Skip to main content

Table 3 Therapeutic regimen in IMN patients with and without coexisting DM

From: The impact of coexisting diabetes mellitus on clinical outcomes in patients with idiopathic membranous nephropathy: a retrospective observational study

Therapeutic regimen

Total

(n = 206)

Non-DM

(n = 164)

DM

(n = 42)

P-value

Non-Immunosuppressive therapy (n, %)

54 (26.2)

44 (26.8)

10 (23.8)

0.691

Immunosuppressive therapy (n, %)

152 (73.8)

120 (73.2)

32 (76.2)

 

Glucocorticoids dosage (g)

1.8 (1.8,2.7)

1.8 (1.8,2.7)

1.8 (1.9,3.4)

0.586

CTX (n, %)

20 (9.7)

12 (7.3)

8 (19.0)

0.037

CsA (n, %)

96 (46.6)

76 (46.4)

20 (47.6)

0.882

FK506 (n, %)

23 (11.2)

20 (12.2)

3 (7.2)

0.425

Othera(n, %)

13 (6.3)

12 (7.3)

1 (2.4)

0.474

  1. Data were expressed as numbers (%). All immunosuppressive therapy was combined with glucocorticoids
  2. DM diabetes mellitus, CTX cyclophosphamide, CsA ciclosporin, FK506 tacrolimus
  3. aother therapeutic regimens included mycophenolate mofetil and glucocorticoids, rituximab and glucocorticoids